Home Cart Sign in  
Chemical Structure| 57053-02-8 Chemical Structure| 57053-02-8

Structure of 57053-02-8

Chemical Structure| 57053-02-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 57053-02-8 ]

CAS No. :57053-02-8
Formula : C10H11NO4
M.W : 209.20
SMILES Code : O=C(C1=CC=CC(C(OC)=O)=C1N)OC
MDL No. :MFCD18431747
InChI Key :QVBQPOJYBWWILD-UHFFFAOYSA-N
Pubchem ID :12217545

Safety of [ 57053-02-8 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 57053-02-8 ] Show Less

Physicochemical Properties

Num. heavy atoms 15
Num. arom. heavy atoms 6
Fraction Csp3 0.2
Num. rotatable bonds 4
Num. H-bond acceptors 4.0
Num. H-bond donors 1.0
Molar Refractivity 53.41
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

78.62 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.89
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.47
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

0.85
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.26
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.92
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.28

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.1
Solubility 1.68 mg/ml ; 0.00803 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.73
Solubility 0.392 mg/ml ; 0.00187 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.2
Solubility 1.33 mg/ml ; 0.00634 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.53 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

2.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.54

Application In Synthesis of [ 57053-02-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 57053-02-8 ]

[ 57053-02-8 ] Synthesis Path-Downstream   1~54

  • 1
  • [ 57053-02-8 ]
  • [ 108-24-7 ]
  • [ 105910-10-9 ]
  • 2
  • [ 57053-02-8 ]
  • 2-methoxy-4-oxo-2-thioxo-1,4-dihydro-2<i>H</i>-2λ5-benzo[<i>d</i>][1,3,2]thiazaphosphinine-8-carboxylic acid methyl ester [ No CAS ]
  • 3
  • [ 57053-02-8 ]
  • 2-methoxy-4-oxo-2-thioxo-1,4-dihydro-2<i>H</i>-2λ5-benzo[<i>d</i>][1,3,2]thiazaphosphinine-8-carbothioic acid <i>O</i>-methyl ester [ No CAS ]
  • 4
  • [ 57053-02-8 ]
  • [ 57053-03-9 ]
  • 5
  • [ 696-59-3 ]
  • [ 57053-02-8 ]
  • [ 89207-99-8 ]
YieldReaction ConditionsOperation in experiment
EXAMPLE 10 Dimethyl 2-(chlorosulfonyl)-1,3-benzenedicarboxy] and from 2-amino-1,3-benzenedicarboxylate To a mixture of 20 g dimethyl 2-amino-1,3-benzenedicarboxylate prepared by the procedures of Scheme 3 (Hirsch et al., J. Org. Chem. 39, p. 2044-8 (1974) in 150 ml concentrated HCl at 0-5 was added, dropwise, a solution of 7.2 g sodium nitrite in 10 ml water over 10 minutes.
  • 7
  • [ 57053-02-8 ]
  • [ 57053-06-2 ]
  • 8
  • [ 57053-02-8 ]
  • [ 57053-16-4 ]
  • 9
  • [ 57053-02-8 ]
  • [ 57053-04-0 ]
  • 10
  • [ 253120-47-7 ]
  • [ 18107-18-1 ]
  • [ 57053-02-8 ]
YieldReaction ConditionsOperation in experiment
With methanol; In tetrahydrofuran; diethyl ether; at 20℃; Trimethylsilyldiazaomethane (9.12 mL, 18.24 mmol) (2M in diethyl ether) was added slowly to a solution of 2-amino-3-(methoxycarbonyl)benzoic acid (2.0 g, 10.25 mmol) in anhydrous 9 mL tetrahydrofuran and 6 mL methanol then the mixture was stirred overnight at room temperature. The reaction mixture was concentrated and purified by flashchromatography (1-6% methanol/CH2Cl2) to afford the title compound.
  • 11
  • [ 57053-02-8 ]
  • [ 1418315-96-4 ]
  • 12
  • [ 57053-02-8 ]
  • [ 1418315-98-6 ]
  • 13
  • [ 57053-02-8 ]
  • [ 1418315-41-9 ]
  • 14
  • [ 57053-02-8 ]
  • [ 1418315-42-0 ]
  • 15
  • [ 57053-02-8 ]
  • [ 1418315-43-1 ]
  • 16
  • [ 57053-02-8 ]
  • [ 7143-01-3 ]
  • [ 1418315-95-3 ]
YieldReaction ConditionsOperation in experiment
With pyridine; at 80℃; A mixture of Example 59A (1.50 g, 7.17 mmol), pyridine (1.74 mL, 21.51 mmol) and methanesulfonic anhydride (2.50 g, 14.34 mmol) in 60 mL 1 ,2-dichloroethane was stirred overnight at 80 C. The reaction mixture was concentrated and the residue was purified by flash chromatography (0-7% methanol/CH2Cl2) to afford the title compound.
  • 19
  • [ 57052-99-0 ]
  • [ 57053-02-8 ]
YieldReaction ConditionsOperation in experiment
99% With palladium 10% on activated carbon; hydrogen; In ethyl acetate; at 20℃; for 20h; Dimethyl 2-aminoisophtalate X (where R1 is methyl). A stream of hydrogen was bubbled through a solution of nitroarene XIV (130 g, 544 mmol, 1.0 eq) and Pd/C (10%,dry, 7.95 g, 6.31 mmol, 1.2 mol%) in regular ethyl acetate (1450 mL) at room temperature. Completion was obtained within 20 h as indicated by TLC analysis. However the reaction time greatly varied depending on the scale and conditions used. The mixture was filtered through a sintered funnel and Pd/C was recovered and successfully reused in other hydrogenations. In the case where wet Pd/C was used,the filtrate was first dried over anhydrous sodium sulphate. The solvents were removed under vacuum to give the desired aniline X (where R1 is methyl) (113 g, 99%) in excellent purity and as a smelly off-white powder. (CAS 57053-02-3)
  • 20
  • [ 57053-02-8 ]
  • 2,6-di(nonan-5-yl)aniline [ No CAS ]
  • 22
  • [ 57053-02-8 ]
  • N,N'-bis[2,6-di(heptan-4-yl)phenyl]diazabutadiene [ No CAS ]
  • 23
  • [ 57053-02-8 ]
  • N,N'-bis [2,6-di(nonan-5-yl)phenyl]diazabutadiene [ No CAS ]
  • 25
  • [ 57053-02-8 ]
  • 1,3-bis[2,6-di(heptan-4-yl)phenyl]imidazolium chloride [ No CAS ]
  • 26
  • [ 57053-02-8 ]
  • 1,3-bis[2,6-di(nonan-5-yl)phenyl]imidazolium chloride [ No CAS ]
  • 27
  • [ 57053-02-8 ]
  • 1,3-bis(2,6-bis(1-ethylpropyl)phenyl)imidazol-2-ylidene [ No CAS ]
  • 28
  • [ 57053-02-8 ]
  • 1,3-bis(2,6-di(3-heptyl)phenyl)imidazolyliden [ No CAS ]
  • 29
  • [ 57053-02-8 ]
  • 1,3-bis(2,6-di(5-nonyl)phenyl)imidazolylidene [ No CAS ]
  • 30
  • [ 57053-02-8 ]
  • [Ni(N,N’-bis(2,6-di(3-pentyl)phenyl)imidazol-2-ylidene)(CO)3] [ No CAS ]
  • 31
  • [ 57053-02-8 ]
  • [Ni(N,N’-bis(2,6-di(4-heptyl)phenyl)imidazol-2-ylidene)(CO)3] [ No CAS ]
  • 32
  • [ 57053-02-8 ]
  • [Ni(N,N’-bis(2,6-di(5-nonyl)phenyl)imidazol-2-ylidene)(CO)3] [ No CAS ]
  • 33
  • [ 57053-02-8 ]
  • [Pd(N,N’-bis(2,6-di(3-pentyl)phenyl)imidazol-2-ylidene)(cinnamyl)Cl] [ No CAS ]
  • 34
  • [ 57053-02-8 ]
  • [Pd(N,N’-bis(2,6-di(4-heptyl)phenyl)imidazol-2-ylidene)(cinnamyl)Cl] [ No CAS ]
  • 35
  • [ 57053-02-8 ]
  • [Pd(N,N’-bis(2,6-di(5-nonyl)phenyl)imidazol-2-ylidene)(cinnamyl)Cl] [ No CAS ]
  • 36
  • [ 57053-02-8 ]
  • [Pd(N,N’-bis(2,6-di(3-pentyl)phenyl)imidazol-2-ylidene)(acetylacetonate)Cl] [ No CAS ]
  • 37
  • [ 57053-02-8 ]
  • [Pd(N,N’-bis(2,6-di(4-heptyl)phenyl)imidazol-2-ylidene)(acetylacetonate)Cl] [ No CAS ]
  • 38
  • [ 57053-02-8 ]
  • [Pd(N,N’-bis(2,6-di(5-nonyl)phenyl)imidazol-2-ylidene)(acetylacetonate)Cl] [ No CAS ]
  • 39
  • [ 57053-02-8 ]
  • 2,6-bis(1-ethylpropyl)aniline [ No CAS ]
  • 40
  • [ 57053-02-8 ]
  • 2,6-di(heptan-4-yl)aniline [ No CAS ]
  • 44
  • [ 74-96-4 ]
  • [ 57053-02-8 ]
  • 2,6-di(3-hydroxypentan-3-yl)aniline [ No CAS ]
YieldReaction ConditionsOperation in experiment
2,6-Di(3-hydroxypentan-3-yl)aniline Xla (R2 = Me).A solution of ethylmagnesium bromide was prepared under strictly anhydrousconditions from commercially available magnesium and ethylbromide. A suspension offresh magnesium (105 g, 4.33 mol, 9.0 eq) in anhydrous THE (1700 mL) was treated with the slow addition of a premade solution of ethylbromide (285 mL, 3.82 mol, 8.0 eq) in anhydrous THF (1700 mL) over I h in maintaining the temperature below 40 00. After 2 h at room temperature, the suspension was cooled down to 0 C, causing theformation of a precipitate, and the diester X (where R1 is methyl) (100 g, 0.48 mol, 1.0 eq) was carefully added portionwise over s mm at 0 00. The reaction was allowed to warm up to room temperature and was stirred until completion as indicated by TLC analysis (< 1 h). The reaction was then cooled down to 0 00 and carefully quenched with sat. NH4CI solution (500 mL). The mixture was diluted in Et20 (1700 mL) andwashed with sat. NH4CI solution (2 x 500 mL). The organic layer was then dried over anhydrous magnesium sulphate and concentrated under vacuum. The resulting crude oil was then filtered thru a pad of silica and flushed with Et20 to get a more accurate yield. Evaporation of the solvent provided the crude diol XIa (116 g, 91%) as a yellow/greenish oil in excellent purity. No further purification was required for the nextsteps.1H NMR (400 MHz, ODd3) 80.84 (12H, app t, J = 7.4 Hz, 4 x OH3), 1.92 (4H, m, 4 x OH), 2.05 (4H, m, 4 x OH), 4.26 (2H, vbs, NH2), 6.57 (1 H, t, J = 7.7 Hz, H-j, 6.92 (2H, d, J = 7.7 Hz, H1). 13C {1H) NMR (100 MHz, CDCI3) 8 8.3 (4 x CH3), 30.8 (4 x CH2), 79.9 (2 x C,-OH),115.4 (CH?), 126.8 (2 x CHmAr), 128.2(2 x CHOAI), 146.7 (CrNH2).HRMS (NSI+): found mlz [M + H]+ 266.2115, calcd for C16H23N02 266.2115.
  • 45
  • [ 57053-02-8 ]
  • [ 106-94-5 ]
  • 2,6-di(4-hydroxyheptan-4-yl)aniline [ No CAS ]
YieldReaction ConditionsOperation in experiment
86% 2,6-Di(4-hydroxyheptan-4-yl)aniline Xlb (R2 = B). A suspension of fresh magnesium (20.9 g, 0.86 mol, 8.6 eq) in anhydrous THF (300 mL) was treated with the slow addition of a premade solution of n-propylbromide (69.5 mL, 0.77 mol, 7.7 eq) in anhydrous THF (300 mL) over 20 mm in maintaining the temperature below 40 DC. After 1.5 h at room temperature, the suspension was cooled down to 0 DC, causing theformation of a precipitate, and a premade solution of diester X (where R1 is methyl) (20.0 g, 0.10 mol, 1.0 eq) in dry THF (300 mL) was cannulated at 0 DC. The reaction was allowed to warm up to room temperature and was stirred for 2 h. The reaction was then cooled down to 0 DC and carefully quenched with sat. NH4CI solution (300 mL). The mixture was diluted in Et20 (400 mL) and washed with sat. NH4CI solution (2 x 200mL). The organic layer was then dried over anhydrous magnesium sulphate and concentrated under vacuum. The resulting brown crude solid (30.9 g) (Pure by 1H NMR) was then further purified by successive recrystallisation from pentane to give the pure diol XIb (26.6 g, 86%) as a white crystalline solid.1H NMR (400 MHz, CDCI3) 60.90 (12H, app t, J = 7.3 Hz, 4 x CH3), 1.08-1.23 (4H, m,4 x CH), 1.26-1.41 (4H, m, 4 x CH), 1.78-1.88 (4H, td, J = 12.5, 4.5 Hz, 4 x CH), 1.95-2.05 (4H, td, J =12.5, 4.5 Hz, 4 x CH), 4.24 (3H, vbs, NH2 + 2 x OH), 6.54 (1H, t, J =7.7 Hz, H), 6.89 (2H, d, J = 7.7 Hz, H?).13C {H} NMR (100 MHz, COd3) 6 14.5(4 x CH3), 17.2(4 x CH2), 41.2 (4 x CH2), 79.4(2 x C,-OH), 115.1 (CH/1), 126.5(2 x CH(nAr), 128.7(2 x CHOAr), 146.7 (CivNH2). HRMS (NSI+): found m/z [M + H]+ 322.2745, calcd for C20H36O2N 322.2741.
  • 46
  • [ 109-65-9 ]
  • [ 57053-02-8 ]
  • 2,6-di(5-hydroxynonan-5-yl)aniline [ No CAS ]
YieldReaction ConditionsOperation in experiment
97% 2,6-Di(5-hydroxynonan-5-yl)aniline Xlc (R2 = n-Pr). A solution of n-butylmagnesium bromide was prepared under strictly anhydrous conditions from commercially availablemagnesium and n-butylbromide as followed. A suspension of fresh magnesium (16.0 g,0.66 mol, 9.4 eq) in anhydrous THF (200 mL) was treated with the slow addition of apremade solution of n-butylbromide (58.0 mL, 0.54 mol, 7.7 eq) in anhydrous THF (200mL) over 1 h in maintaining the temperature below 40 C. After 2 h at roomtemperature, the suspension was cooled down to 0 C, causing the formation of aprecipitate, and a solution of diester X (where R1 is methyl) (14.0 g, 0.07 mol, 1.0 eq) in dry THE (200 mL) was cannulated at 0 C. The reaction was allowed to warm up to room temperature and was stirred until completion as indicated by TLC analysis (< 1 h). The reaction was then cooled down to 0 ?C and carefully quenched with sat. NH4CI solution (200 mL). The mixture was diluted in Et20 (250 mL) and washed with sat.NH4CI solution (2 x 150 mL). The organic layer was then dried over anhydrous magnesium sulphate and concentrated under vacuum. The resulting brownish crude solid (pure by 1H NMR) was then recrystallized from hot pentane to give the pure diol Xlc (24.4 g, 97%) as an off-white crystalline solid.1iI NMR (400 MHz, CDCI3) 8 0.88 (12H, app t, J = 7.2 Hz, 4 x OH3), 1.14 (4H, m, 4 x OH), 1.32 (12H, m, 12 x OH), 1.87 (4H, m, 4 x OH), 2.03 (4H, m, 4 x CH), 2.24 (2H, partially hidden vbs, 2 x OH), 5.98 (2H, vbs, NH2), 6.56 (1H, t, J = 7.9 Hz, Hr), 6.91 (2H, d, J = 7.9 Hz, i-r?-j.13C {I-I} NMR (100 MHz, CDCI3) 8 14.0 (4 x OH3), 23.1 (4 x OH2), 26.1 (4 x OH2), 38.1(4 x OH2), 79.3 (2 x Ow-OH), 115.0 (OHfrAr), 126.5 (2 x OHmAr), 128.4 (2 x OHj,146.7 (OivNH2).HRMS (NSI+): found m/z [M + H]+ 378.3369, calcd for O24H44NO2 378.3367.
  • 47
  • [ 57053-02-8 ]
  • [Pd(IPent)(η3-cinnamyl)Cl] [ No CAS ]
  • 52
  • [ 57053-02-8 ]
  • 4-hydroxy-2-phenylquinazoline-8-carboxamide [ No CAS ]
  • 53
  • [ 57053-02-8 ]
  • 4-hydroxy-2-phenylquinazoline-8-carbonitrile [ No CAS ]
  • 54
  • [ 57053-02-8 ]
  • 4-(phenethylamino)-2-phenylquinazoline-8-carbonitrile [ No CAS ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 57053-02-8 ]

Aryls

Chemical Structure| 22223-49-0

A122057 [22223-49-0]

Methyl 2-amino-3-methylbenzoate

Similarity: 0.98

Chemical Structure| 18595-13-6

A143560 [18595-13-6]

Methyl 2-amino-6-methylbenzoate

Similarity: 0.96

Chemical Structure| 41684-07-5

A163907 [41684-07-5]

4-Amino-3-(methoxycarbonyl)benzoic acid

Similarity: 0.96

Chemical Structure| 63746-12-3

A415401 [63746-12-3]

Dimethyl 4-aminoisophthalate

Similarity: 0.96

Chemical Structure| 49592-84-9

A115493 [49592-84-9]

Methyl 2,5-Diaminobenzoate

Similarity: 0.96

Esters

Chemical Structure| 22223-49-0

A122057 [22223-49-0]

Methyl 2-amino-3-methylbenzoate

Similarity: 0.98

Chemical Structure| 18595-13-6

A143560 [18595-13-6]

Methyl 2-amino-6-methylbenzoate

Similarity: 0.96

Chemical Structure| 41684-07-5

A163907 [41684-07-5]

4-Amino-3-(methoxycarbonyl)benzoic acid

Similarity: 0.96

Chemical Structure| 63746-12-3

A415401 [63746-12-3]

Dimethyl 4-aminoisophthalate

Similarity: 0.96

Chemical Structure| 49592-84-9

A115493 [49592-84-9]

Methyl 2,5-Diaminobenzoate

Similarity: 0.96

Amines

Chemical Structure| 22223-49-0

A122057 [22223-49-0]

Methyl 2-amino-3-methylbenzoate

Similarity: 0.98

Chemical Structure| 18595-13-6

A143560 [18595-13-6]

Methyl 2-amino-6-methylbenzoate

Similarity: 0.96

Chemical Structure| 41684-07-5

A163907 [41684-07-5]

4-Amino-3-(methoxycarbonyl)benzoic acid

Similarity: 0.96

Chemical Structure| 63746-12-3

A415401 [63746-12-3]

Dimethyl 4-aminoisophthalate

Similarity: 0.96

Chemical Structure| 49592-84-9

A115493 [49592-84-9]

Methyl 2,5-Diaminobenzoate

Similarity: 0.96